University College London Hospitals NHS Foundation Trust

London, England WC1N 3BG

3 studies enrolling now · 11 studies all time

What they study most

Advanced Non-Small-Cell Lung Cancer, Bladder Cancer, Cervical Carcinoma, Cervix Cancer, Colo-rectal Cancer, Diffuse Large B-cell Lymphoma, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations, Early Parkinson Disease (Early PD), Endometrium Cancer, Esophageal Cancer

Studies at this site

• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations — Recruiting now
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease — Recruiting now
• A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis — Recruiting now
• Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma — Stopped early
• A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) — Stopped early
• A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma — Stopped early
• Study of ADCT-301 in Patients With Selected Advanced Solid Tumors — Stopped early
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) — Completed
• TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Stopped early
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors — Completed
• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET — Completed